Antimüllerian Hormone to Determine Polycystic Ovarian Morphology: The APHRODITE Study

The APHRODITE study, a retrospective, multicenter, case-control study involving 2,014 participants, aimed to determine a cutoff for the Elecsys AMH Plus immunoassay to identify polycystic ovarian morphology (PCOM), a criterion for polycystic ovary syndrome (PCOS). The study found that a serum Antimüllerian hormone (AMH) cutoff of 3.2 ng/mL resulted in a sensitivity of 88.6% and specificity of 84.6% for PCOM diagnosis, with similar results across PCOS phenotypes A–D. The study concluded that the Elecsys AMH Plus immunoassay is a robust method for identifying PCOM to aid in PCOS diagnosis. The study also found that body mass index (BMI) and race had no significant effect on case-control status. The findings are generalizable to European women aged 25–45 years with symptoms suggestive of PCOS.